Brief: Medigene: Clinical Trial Agreement For HA-1 TCR Immunotherapy MDG1021 With University Of Leiden
22/05/2019 06:31
May 22 (Reuters) - Medigene AG MDG1k.DE :
* PTA-NEWS: MEDIGENE AG: MEDIGENE ANNOUNCES CLINICAL TRIAL AGREEMENT FOR HA-1 TCR
IMMUNOTHERAPY
MDG1021 WITH UNIVERSITY OF LEIDEN
* CLINICAL TRIAL START SCHEDULED FOR 2020
Source text for Eikon: ID:nPexjrPSZa
Further company coverage: MDG1k.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Medigene AG
See all newsBrief: Medigene Files Application For The Opening Of Insolvency Proceedings
Brief: Medigene Files Patent For Unique Nk-Specific TCR Construct With European Patent Office
Brief: Medigene AG Says Co Amends Financial Guidance For 2024
Brief: Medigene AG Expands Protection Of KRAS Library With Filing Of New Patent Application
Brief: Medigene H1 Revenue EUR 4.5 Million